vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and WEX Inc. (WEX). Click either name above to swap in a different company.

WEX Inc. is the larger business by last-quarter revenue ($652.7M vs $487.7M, roughly 1.3× CLOVER HEALTH INVESTMENTS, CORP.). WEX Inc. runs the higher net margin — 10.1% vs -10.1%, a 20.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -3.1%). WEX Inc. produced more free cash flow last quarter ($-9.2M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 16.8%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

WEX Inc. is a provider of payment processing and information management services to the United States commercial and government vehicle fleet industry. The company is headquartered in Portland, Maine and provides services in the United States, Canada, South America, Europe, Asia, and Australia.

CLOV vs WEX — Head-to-Head

Bigger by revenue
WEX
WEX
1.3× larger
WEX
$652.7M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+47.9% gap
CLOV
44.7%
-3.1%
WEX
Higher net margin
WEX
WEX
20.2% more per $
WEX
10.1%
-10.1%
CLOV
More free cash flow
WEX
WEX
$59.8M more FCF
WEX
$-9.2M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
16.8%
WEX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
WEX
WEX
Revenue
$487.7M
$652.7M
Net Profit
$-49.3M
$65.8M
Gross Margin
Operating Margin
-10.1%
25.2%
Net Margin
-10.1%
10.1%
Revenue YoY
44.7%
-3.1%
Net Profit YoY
-123.2%
-15.3%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
WEX
WEX
Q1 26
$652.7M
Q4 25
$487.7M
$465.1M
Q3 25
$496.6M
$481.6M
Q2 25
$477.6M
$454.4M
Q1 25
$462.3M
$444.3M
Q4 24
$337.0M
$440.3M
Q3 24
$331.0M
$479.0M
Q2 24
$356.3M
$478.6M
Net Profit
CLOV
CLOV
WEX
WEX
Q1 26
$65.8M
Q4 25
$-49.3M
$84.2M
Q3 25
$-24.4M
$80.3M
Q2 25
$-10.6M
$68.1M
Q1 25
$-1.3M
$71.5M
Q4 24
$-22.1M
$63.9M
Q3 24
$-9.2M
$102.9M
Q2 24
$7.4M
$77.0M
Gross Margin
CLOV
CLOV
WEX
WEX
Q1 26
Q4 25
39.0%
Q3 25
43.0%
Q2 25
40.0%
Q1 25
39.2%
Q4 24
41.5%
Q3 24
24.5%
48.0%
Q2 24
30.3%
44.9%
Operating Margin
CLOV
CLOV
WEX
WEX
Q1 26
25.2%
Q4 25
-10.1%
35.7%
Q3 25
-4.9%
38.1%
Q2 25
-2.2%
34.5%
Q1 25
-0.3%
35.4%
Q4 24
-6.4%
35.7%
Q3 24
-2.7%
41.0%
Q2 24
2.0%
35.1%
Net Margin
CLOV
CLOV
WEX
WEX
Q1 26
10.1%
Q4 25
-10.1%
18.1%
Q3 25
-4.9%
16.7%
Q2 25
-2.2%
15.0%
Q1 25
-0.3%
16.1%
Q4 24
-6.6%
14.5%
Q3 24
-2.8%
21.5%
Q2 24
2.1%
16.1%
EPS (diluted)
CLOV
CLOV
WEX
WEX
Q1 26
Q4 25
$2.38
Q3 25
$2.30
Q2 25
$1.98
Q1 25
$1.81
Q4 24
$1.60
Q3 24
$2.52
Q2 24
$1.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
WEX
WEX
Cash + ST InvestmentsLiquidity on hand
$78.3M
$780.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
Total Assets
$541.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
WEX
WEX
Q1 26
$780.0M
Q4 25
$78.3M
$5.2B
Q3 25
$4.9B
Q2 25
$4.9B
Q1 25
$4.4B
Q4 24
$194.5M
$4.4B
Q3 24
$288.0M
$4.3B
Q2 24
$254.8M
$4.0B
Stockholders' Equity
CLOV
CLOV
WEX
WEX
Q1 26
Q4 25
$308.7M
$1.2B
Q3 25
$340.9M
$1.1B
Q2 25
$344.2M
$978.7M
Q1 25
$336.1M
$810.4M
Q4 24
$341.1M
$1.5B
Q3 24
$342.2M
$1.7B
Q2 24
$324.9M
$1.8B
Total Assets
CLOV
CLOV
WEX
WEX
Q1 26
Q4 25
$541.0M
$14.4B
Q3 25
$559.7M
$14.4B
Q2 25
$575.0M
$14.7B
Q1 25
$583.7M
$14.0B
Q4 24
$580.7M
$13.3B
Q3 24
$653.0M
$14.0B
Q2 24
$674.2M
$14.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
WEX
WEX
Operating Cash FlowLast quarter
$-66.9M
Free Cash FlowOCF − Capex
$-69.0M
$-9.2M
FCF MarginFCF / Revenue
-14.1%
-1.4%
Capex IntensityCapex / Revenue
0.4%
5.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$818.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
WEX
WEX
Q1 26
Q4 25
$-66.9M
$294.7M
Q3 25
$12.1M
$376.6M
Q2 25
$5.4M
$264.6M
Q1 25
$-16.3M
$-481.6M
Q4 24
$34.8M
$638.4M
Q3 24
$50.0M
$3.3M
Q2 24
$44.8M
$-7.0M
Free Cash Flow
CLOV
CLOV
WEX
WEX
Q1 26
$-9.2M
Q4 25
$-69.0M
$256.3M
Q3 25
$11.4M
$341.6M
Q2 25
$4.8M
$230.0M
Q1 25
$-16.5M
$-514.2M
Q4 24
$33.3M
$599.7M
Q3 24
$49.6M
$-31.7M
Q2 24
$44.4M
$-46.6M
FCF Margin
CLOV
CLOV
WEX
WEX
Q1 26
-1.4%
Q4 25
-14.1%
55.1%
Q3 25
2.3%
70.9%
Q2 25
1.0%
50.6%
Q1 25
-3.6%
-115.7%
Q4 24
9.9%
136.2%
Q3 24
15.0%
-6.6%
Q2 24
12.5%
-9.7%
Capex Intensity
CLOV
CLOV
WEX
WEX
Q1 26
5.2%
Q4 25
0.4%
8.3%
Q3 25
0.1%
7.3%
Q2 25
0.1%
7.6%
Q1 25
0.0%
7.3%
Q4 24
0.5%
8.8%
Q3 24
0.1%
7.3%
Q2 24
0.1%
8.3%
Cash Conversion
CLOV
CLOV
WEX
WEX
Q1 26
Q4 25
3.50×
Q3 25
4.69×
Q2 25
3.89×
Q1 25
-6.74×
Q4 24
9.99×
Q3 24
0.03×
Q2 24
6.04×
-0.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons